Your email has been successfully added to our mailing list.

×
0.00185185185185181 0.00185185185185181 0.00185185185185181 0.00185185185185181 0.00185185185185181 0.00185185185185181 0.00185185185185181 0.00185185185185181
Stock impact report

Catabasis Pharmaceuticals Announces the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy has Exceeded Target Enrollment

Catabasis Pharmaceuticals, Inc. (CATB) 
Last catabasis pharmaceuticals, inc. earnings: 3/10 08:05 am Check Earnings Report
US:NASDAQ Investor Relations: ir.catabasis.com/investor-overview
Company Research Source: Business Wire
-- Top-line Results Expected Fourth Quarter of 2020 -- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today the completion of enrollment for the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD). The target enrollment of 125 boys was exceeded due to strong interest from our 40 clinical sites in 8 countries and the support of patient advocacy organizations. Top-line results from the Phase 3 PolarisDMD trial are expected in the fourth quarter of 2020 and the trial is anticipated to support an NDA filing in 2021.“We are thrilled to reach this important milestone. The interest and feedback from families and trial sites has been overwhelmingly positive. At a time when there are multiple trials for Duchenne, we are very pleased that physicians and families chose the Phase 3 PolarisDMD trial for edasalonexent,” said Joanne Donovan, M.D., Ph.D., Chief Medical Officer of Cat Show less Read more
Impact Snapshot
Event Time:
CATB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for CATB alerts
Opt-in for
CATB alerts

from News Quantified
Opt-in for
CATB alerts

from News Quantified